BACKGROUND: IL-5 plays a central role in the development and maintenance of eosinophilia (EO) and eosinophil activation in a wide variety of eosinophilic disorders. Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo. OBJECTIVE: To assess soluble and surface IL-5Rα levels in patients with EO and/or mastocytosis. METHODS: Surface IL-5Rα expression was assessed by flow cytometry in blood and/or bone marrow from subjects with EO (n = 39) and systemic mastocytosis (n = 8) and from normal volunteers (n = 28). Soluble IL-5Rα (sIL-5Rα) level was measured in a cohort of 177 untreated subjects and correlated with EO, eosinophil activation, and serum tryptase and cytokine levels. RESULTS: IL-5Rα expression on eosinophils inversely correlated with EO (r = -0.48; P < .0001), whereas serum levels of sIL-5Rα increased with the eosinophil count (r = 0.56; P < .0001) and serum IL-5 (r = 0.40; P < .0001) and IL-13 (r = 0.29; P = .004) levels. Of interest, sIL-5Rα level was significantly elevated in patients with systemic mastocytosis without EO. Although sIL-5Rα levels correlated with serum tryptase levels in these patients, eosinophil activation, assessed by CD69 expression on eosinophils and serum eosinophil-derived neurotoxin levels, was increased compared with that in normal subjects. CONCLUSIONS: These data are consistent with an in vivo IL-5Rα regulatory pathway in human eosinophils similar to that described in vitro and involving a balance between soluble and surface receptor levels. This may have implications with respect to the use of novel therapeutic agents targeting IL-5 and its receptor in patients with EO and/or mastocytosis. Published by Mosby, Inc.
BACKGROUND:IL-5 plays a central role in the development and maintenance of eosinophilia (EO) and eosinophil activation in a wide variety of eosinophilic disorders. Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo. OBJECTIVE: To assess soluble and surface IL-5Rα levels in patients with EO and/or mastocytosis. METHODS: Surface IL-5Rα expression was assessed by flow cytometry in blood and/or bone marrow from subjects with EO (n = 39) and systemic mastocytosis (n = 8) and from normal volunteers (n = 28). Soluble IL-5Rα (sIL-5Rα) level was measured in a cohort of 177 untreated subjects and correlated with EO, eosinophil activation, and serum tryptase and cytokine levels. RESULTS:IL-5Rα expression on eosinophils inversely correlated with EO (r = -0.48; P < .0001), whereas serum levels of sIL-5Rα increased with the eosinophil count (r = 0.56; P < .0001) and serum IL-5 (r = 0.40; P < .0001) and IL-13 (r = 0.29; P = .004) levels. Of interest, sIL-5Rα level was significantly elevated in patients with systemic mastocytosis without EO. Although sIL-5Rα levels correlated with serum tryptase levels in these patients, eosinophil activation, assessed by CD69 expression on eosinophils and serum eosinophil-derived neurotoxin levels, was increased compared with that in normal subjects. CONCLUSIONS: These data are consistent with an in vivo IL-5Rα regulatory pathway in human eosinophils similar to that described in vitro and involving a balance between soluble and surface receptor levels. This may have implications with respect to the use of novel therapeutic agents targeting IL-5 and its receptor in patients with EO and/or mastocytosis. Published by Mosby, Inc.
Authors: Allan Hildesheim; Rick L Ryan; Elizabeth Rinehart; Sonali Nayak; Dora Wallace; Philip E Castle; Shelley Niwa; William Kopp Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-11 Impact factor: 4.254
Authors: Lin Ying Liu; Julie B Sedgwick; Mary Ellen Bates; Rose F Vrtis; James E Gern; Hirohita Kita; Nizar N Jarjour; William W Busse; Elizabeth A B Kelly Journal: J Immunol Date: 2002-12-01 Impact factor: 5.422
Authors: J Tavernier; J Van der Heyden; A Verhee; G Brusselle; X Van Ostade; J Vandekerckhove; J North; S M Rankin; A B Kay; D S Robinson Journal: Blood Date: 2000-03-01 Impact factor: 22.113
Authors: Lin Ying Liu; Julie B Sedgwick; Mary Ellen Bates; Rose F Vrtis; James E Gern; Hirohita Kita; Nizar N Jarjour; William W Busse; Elizabeth A B Kelly Journal: J Immunol Date: 2002-12-01 Impact factor: 5.422
Authors: P Gevaert; C Bachert; G Holtappels; C P Novo; J Van der Heyden; L Fransen; S Depraetere; H Walter; P van Cauwenberge; J Tavernier Journal: Allergy Date: 2003-05 Impact factor: 13.146
Authors: Bernard Gregory; Antje Kirchem; Simon Phipps; Phillipe Gevaert; Carol Pridgeon; Sara M Rankin; Douglas S Robinson Journal: J Immunol Date: 2003-06-01 Impact factor: 5.422
Authors: Wolfgang R Sperr; John-Hendrik Jordan; Michael Fiegl; Luis Escribano; Carmen Bellas; Stephan Dirnhofer; Hans Semper; Ingrid Simonitsch-Klupp; Hans-Peter Horny; Peter Valent Journal: Int Arch Allergy Immunol Date: 2002-06 Impact factor: 2.749
Authors: Claudina Pérez; Jo Vandesompele; Ina Vandenbroucke; Gabriele Holtappels; Frank Speleman; Philippe Gevaert; Paul Van Cauwenberge; Claus Bachert Journal: BMC Biotechnol Date: 2003-09-30 Impact factor: 2.563
Authors: Aurelie A Ray; Jeffrey J Fountain; Halli E Miller; Andrea M Cooper; Richard T Robinson Journal: Infect Immun Date: 2014-11-17 Impact factor: 3.441
Authors: Iris M Otani; Arjun A Anilkumar; Robert O Newbury; Monica Bhagat; Lisa Y Beppu; Ranjan Dohil; David H Broide; Seema S Aceves Journal: J Allergy Clin Immunol Date: 2013-04-25 Impact factor: 10.793
Authors: Fanny Legrand; Yun Cao; Joshua B Wechsler; Xiang Zhu; Nives Zimmermann; Shakuntala Rampertaap; Joseph Monsale; Kimberly Romito; Bradford A Youngblood; Emily C Brock; Michelle A Makiya; Nenad Tomasevic; Christopher Bebbington; Irina Maric; Dean D Metcalfe; Bruce S Bochner; Amy D Klion Journal: J Allergy Clin Immunol Date: 2018-12-10 Impact factor: 10.793
Authors: S Prakash Babu; Y-Y K Chen; S Bonne-Annee; J Yang; I Maric; T G Myers; T B Nutman; A D Klion Journal: Allergy Date: 2017-04-18 Impact factor: 13.146